Reviewed,
UniProtKB/Swiss-Prot P78363 (ABCA4_HUMAN)
Last modified
July 22, 2008.
Version 96.
History...
Clusters with 100%,
90%,
50% identity |
Documents (6) |
Third-party data |
Customize display | text xml rdf/xml gff fasta |
Names and origin
| Protein names | Recommended name: Retinal-specific ATP-binding cassette transporter Alternative name(s): ATP-binding cassette sub-family A member 4 RIM ABC transporter Short name=RIM protein Short name=RmP Stargardt disease protein | ||||
| Gene names |
| ||||
| Organism | Homo sapiens (Human) | ||||
| Taxonomic identifier | 9606 [NCBI] | ||||
| Taxonomic lineage | Eukaryota › Metazoa › Chordata › Craniata › Vertebrata › Euteleostomi › Mammalia › Eutheria › Euarchontoglires › Primates › Haplorrhini › Catarrhini › Hominidae › Homo |
Protein attributes
| Sequence length | 2273 AA. |
| Sequence status | Complete. |
| Sequence processing | The displayed sequence is not processed. |
| Protein existence | Evidence at protein level. |
General annotation (Comments)
| Function | May play a role in photoresponse. Retinoids, and most likely retinal, are the natural substrates for transport by abcr in rod outer segments. May act in the visual cycle to flip PE-all-trans-retinal adducts from the lumenal to the cytosolic face of the disk membrane, move free all-trans-retinal from the lipid phase of the disk membrane to a juxtamembrane location, or possibly reorient all-trans-retinal in the bilayer. |
| Subcellular location | |
| Tissue specificity | Retinal-specific. Seems to be exclusively found in the rims of rod photoreceptor cells. |
| Polymorphism | The variant Ala-863 is present in the general population at a frequency of approximately 3% and 1% in Northern Europe and United States, respectively. It is a mild alteration probably leading to STGD phenotype only in combination with a more severe allele. The variant Glu-1961 is found with high frequency in healthy individuals of Somali ancestry. |
| Involvement in disease | Defects in ABCA4 are the cause of Stargardt disease type 1 (STGD1) [MIM:248200]. STGD is one of the most frequent causes of macular degeneration in childhood. It is characterized by macular dystrophy with juvenile-onset, rapidly progressive course, alterations of the peripheral retina, and subretinal deposition of lipofuscin-like material. STGD1 inheritance is autosomal recessive. Defects in ABCA4 are the cause of fundus flavimaculatus (FFM) [MIM:248200]. FFM is an autosomal recessive retinal disorder very similar to Stargardt disease. In contrast to Stargardt disease, FFM is characterized by later onset and slowly progressive course. Defects in ABCA4 may be a cause of age-related macular degeneration type 2 (ARMD2) [MIM:153800]. ARMD is a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid (known as drusen) that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane. Defects in ABCA4 are the cause of cone-rod dystrophy type 3 (CORD3) [MIM:604116]. CORDs are inherited retinal dystrophies belonging to the group of pigmentary retinopathies. CORDs are characterized by retinal pigment deposits visible on fundus examination, predominantly in the macular region, and initial loss of cone photoreceptors followed by rod degeneration. This leads to decreased visual acuity and sensitivity in the central visual field, followed by loss of peripheral vision. Severe loss of vision occurs earlier than in retinitis pigmentosa. Defects in ABCA4 are the cause of retinitis pigmentosa type 19 (RP19) [MIM:601718]. RP leads to degeneration of retinal photoreceptor cells. Patients typically have night vision blindness and loss of midperipheral visual field. As their condition progresses, they lose their far peripheral visual field and eventually central vision as well. RP19 is characterized by choroidal atrophy. Inheritance is autosomal recessive. |
| Sequence similarities | Belongs to the ABC transporter family. ABCA subfamily. Contains 2 ABC transporter domains. |
Ontologies
Keywords | |
|---|---|
| Biological process | Sensory transduction Transport Vision |
| Cellular component | Membrane |
| Coding sequence diversity | Polymorphism |
| Disease | Age-related macular degeneration Cone-rod dystrophy Disease mutation Retinitis pigmentosa Stargardt disease |
| Domain | Repeat Transmembrane |
| Ligand | ATP-binding Nucleotide-binding |
| PTM | Glycoprotein |
Gene Ontology (GO) | |
| Biological process | phototransduction, visible light Ref.2 Traceable author statement. Source: ProtInc transport Ref.1Traceable author statement. Source: ProtInc |
| Cellular component | membrane fraction Ref.1 Traceable author statement. Source: ProtInc |
| Molecular function | ATP binding Ref.1 Traceable author statement. Source: ProtInc ATPase activity, coupled to transmembrane movement of substances Ref.1Traceable author statement. Source: ProtInc |
| Complete GO annotation... | |
Sequence annotation (Features)
| Feature key | Position(s) | Length | Description | Graphical view | ||||
Molecule processing | ||||||||
|---|---|---|---|---|---|---|---|---|
| Chain | 1 – 2273 | 2273 | Retinal-specific ATP-binding cassette transporter | |||||
Regions | ||||||||
| Transmembrane | 22 – 42 | 21 | Potential | |||||
| Transmembrane | 547 – 567 | 21 | Potential | |||||
| Transmembrane | 647 – 667 | 21 | Potential | |||||
| Transmembrane | 700 – 720 | 21 | Potential | |||||
| Transmembrane | 731 – 751 | 21 | Potential | |||||
| Transmembrane | 760 – 780 | 21 | Potential | |||||
| Transmembrane | 836 – 856 | 21 | Potential | |||||
| Transmembrane | 1072 – 1092 | 21 | Potential | |||||
| Transmembrane | 1377 – 1397 | 21 | Potential | |||||
| Transmembrane | 1560 – 1580 | 21 | Potential | |||||
| Transmembrane | 1682 – 1702 | 21 | Potential | |||||
| Transmembrane | 1728 – 1748 | 21 | Potential | |||||
| Transmembrane | 1760 – 1780 | 21 | Potential | |||||
| Transmembrane | 1793 – 1813 | 21 | Potential | |||||
| Transmembrane | 1832 – 1852 | 21 | Potential | |||||
| Transmembrane | 1874 – 1894 | 21 | Potential | |||||
| Domain | 929 – 1160 | 232 | ABC transporter 1 | |||||
| Domain | 1938 – 2170 | 233 | ABC transporter 2 | |||||
| Nucleotide binding | 963 – 970 | 8 | ATP 1 Potential | |||||
| Nucleotide binding | 1972 – 1979 | 8 | ATP 2 Potential | |||||
Amino acid modifications | ||||||||
| Glycosylation | 14 | 1 | N-linked (GlcNAc...) Potential | |||||
| Glycosylation | 98 | 1 | N-linked (GlcNAc...) Potential | |||||
| Glycosylation | 415 | 1 | N-linked (GlcNAc...) Potential | |||||
| Glycosylation | 444 | 1 | N-linked (GlcNAc...) Potential | |||||
| Glycosylation | 504 | 1 | N-linked (GlcNAc...) Potential | |||||
| Glycosylation | 950 | 1 | N-linked (GlcNAc...) Potential | |||||
| Glycosylation | 1469 | 1 | N-linked (GlcNAc...) Potential | |||||
| Glycosylation | 1529 | 1 | N-linked (GlcNAc...) Potential | |||||
| Glycosylation | 1588 | 1 | N-linked (GlcNAc...) Potential | |||||
| Glycosylation | 1662 | 1 | N-linked (GlcNAc...) Potential | |||||
| Glycosylation | 1707 | 1 | N-linked (GlcNAc...) Potential | |||||
| Glycosylation | 1819 | 1 | N-linked (GlcNAc...) Potential | |||||
| Glycosylation | 1933 | 1 | N-linked (GlcNAc...) Potential | |||||
| Glycosylation | 2006 | 1 | N-linked (GlcNAc...) Potential | |||||
| Glycosylation | 2052 | 1 | N-linked (GlcNAc...) Potential | |||||
Natural variations | ||||||||
| Natural variant | 11 | 1 | L → P in FFM. | |||||
| Natural variant | 13 – 15 | 3 | Missing in STGD1. | |||||
| Natural variant | 18 | 1 | R → W in STGD1. | |||||
| Natural variant | 24 | 1 | R → H in STGD1. | |||||
| Natural variant | 54 | 1 | C → Y in STGD1. | |||||
| Natural variant | 58 | 1 | N → K in STGD1. | |||||
| Natural variant | 60 | 1 | A → E in STGD1. | |||||
| Natural variant | 60 | 1 | A → T in STGD1. | |||||
| Natural variant | 60 | 1 | A → V in STGD1. | |||||
| Natural variant | 65 | 1 | G → E in STGD1 and CORD3. | |||||
| Natural variant | 68 | 1 | P → L in STGD1. | |||||
| Natural variant | 68 | 1 | P → R in STGD1. | |||||
| Natural variant | 72 | 1 | G → R in STGD1. | |||||
| Natural variant | 75 | 1 | C → G in STGD1. | |||||
| Natural variant | 77 | 1 | V → E in STGD1. | |||||
| Natural variant | 96 | 1 | N → D in STGD1. | |||||
| Natural variant | 96 | 1 | N → H in STGD1. | |||||
| Natural variant | 100 | 1 | S → P in STGD1. | |||||
| Natural variant | 152 | 1 | R → Q | |||||
| Natural variant | 156 | 1 | I → V in STGD1. | |||||
| Natural variant | 190 | 1 | Q → H in STGD1. | |||||
| Natural variant | 192 | 1 | A → T in STGD1. | |||||
| Natural variant | 206 | 1 | S → R in STGD1; reduced basal and retinal-stimulated ATP-hydrolysis. | |||||
| Natural variant | 212 | 1 | R → C in STGD1 and CORD3; common mutation in southern Europe; reduced ATP-binding capacity. | |||||
| Natural variant | 212 | 1 | R → H | |||||
| Natural variant | 220 | 1 | R → C in STGD1. | |||||
| Natural variant | 224 | 1 | T → M in a breast cancer sample; somatic mutation. | |||||
| Natural variant | 230 | 1 | C → S in STGD1. | |||||
| Natural variant | 244 | 1 | L → P in STGD1. | |||||
| Natural variant | 247 | 1 | N → S in STGD1. | |||||
| Natural variant | 249 | 1 | D → G in STGD1. | |||||
| Natural variant | 300 | 1 | T → N in STGD1. | |||||
| Natural variant | 309 | 1 | P → R in STGD1. | |||||
| Natural variant | 328 | 1 | E → V in STGD1. | |||||
| Natural variant | 333 | 1 | R → W in STGD1. | |||||
| Natural variant | 336 | 1 | S → C in STGD1. | |||||
| Natural variant | 339 | 1 | W → G in FFM. | |||||
| Natural variant | 340 | 1 | Y → D in STGD1. | |||||
| Natural variant | 380 | 1 | N → K in STGD1. | |||||
| Natural variant | 407 | 1 | A → V in STGD1 and CORD3. | |||||
| Natural variant | 423 | 1 | H → R | |||||
| Natural variant | 445 | 1 | S → R in STGD1. | |||||
| Natural variant | 471 | 1 | E → K in ARMD2 and STGD1; ATP-binding capacity and retinal stimulation as in wild-type. dbSNP rs1800548. | |||||
| Natural variant | 523 | 1 | D → E in STGD1. | |||||
| Natural variant | 525 | 1 | F → C in STGD1. | |||||
| Natural variant | 537 | 1 | R → C in STGD1. | |||||
| Natural variant | 541 | 1 | L → P in STGD1, FFM and CORD3; reduced ATP-binding capacity; abolishes retinal-stimulated ATP hydrolysis. | |||||
| Natural variant | 549 | 1 | A → P in STGD1. | |||||
| Natural variant | 550 | 1 | G → R in STGD1. | |||||
| Natural variant | 552 | 1 | V → I | |||||
| Natural variant | 572 | 1 | R → P in STGD1. | |||||
| Natural variant | 572 | 1 | R → Q in STGD1. | |||||
| Natural variant | 602 | 1 | R → Q in STGD1. | |||||
| Natural variant | 602 | 1 | R → W in STGD1. | |||||
| Natural variant | 607 | 1 | G → R in STGD1. | |||||
| Natural variant | 607 | 1 | G → W in STGD1. | |||||
| Natural variant | 608 | 1 | F → I in STGD1. | |||||
| Natural variant | 635 | 1 | Q → K in STGD1. | |||||

Clusters with